Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
Baxter
US Department of Justice
Federal Trade Commission
Boehringer Ingelheim
Cipla
Julphar
Mallinckrodt
Covington

Generated: June 24, 2018

DrugPatentWatch Database Preview

NOLUDAR Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Noludar patents expire, and what generic alternatives are available?

Noludar is a drug marketed by Roche and is included in one NDA.

The generic ingredient in NOLUDAR is methyprylon. Additional details are available on the methyprylon profile page.
Summary for NOLUDAR
Drug patent expirations by year for NOLUDAR
Synonyms for NOLUDAR
(?)-Noludar
(+)-Noludar
125-64-4
2, 3,3-diethyl-5-methyl-
2,3-diethyl-5-methylpiperidine
2,4-Dioxo-3,3-diethyl-5-methylpiperidine
2,4-Dioxy-3,3-diethyl-5-methylpiperidine
2,4-Piperidinedione, 3,3-diethyl-5-methyl-
3,3-Diethyl-2,4-dioxo-5-methylpiperidine
3,3-Diethyl-5-methyl-2,4-piperidinedione
3,3-Diethyl-5-methylpiperidine-2,4-dione
3,4-dioxo-5-methylpiperidine
5,5-diethyl-6-hydroxy-3-methyl-2,3,4,5-tetrahydropyridin-4-one
AC1L1HJV
ACM125644
AKOS006239549
BRN 0082860
C10H17NO2
CHEBI:31837
CHEMBL1200790
D01150
D05OQJ
DB01107
DEA No. 2575
Dimerin
DTXSID7023306
EINECS 204-745-4
FCH834496
GTPL7238
HE039380
HE303875
HSDB 3128
LS-115204
Methprylon
Methyprolon
methyprylon
Methyprylon (JAN/INN)
Methyprylon [INN]
Methyprylone
Methyprylone [INN-French]
Methyprylonum
Methyprylonum [INN-Latin]
Metiprilon
Metiprilona
Metiprilona [INN-Spanish]
Metiprilone
Noctan
Nodular
Noludar (TN)
NSC 30442
NSC-30442
NSC30442
Ro 1-6463
SCHEMBL155838
SIDLZWOQUZRBRU-UHFFFAOYSA-N
WLN: T6MV DVTJ C2 C2 E1

US Patents and Regulatory Information for NOLUDAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Roche NOLUDAR methyprylon CAPSULE;ORAL 009660-008 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Roche NOLUDAR methyprylon TABLET;ORAL 009660-004 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Roche NOLUDAR methyprylon ELIXIR;ORAL 009660-007 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Roche NOLUDAR methyprylon TABLET;ORAL 009660-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Baxter
Daiichi Sankyo
Federal Trade Commission
Johnson and Johnson
Deloitte
Express Scripts
Medtronic
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.